Sunshine Biopharma Q1 2025 Earnings Report

Sunshine Biopharma EPS Results

• Actual EPS: -$4.40
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Sunshine Biopharma Revenue Results

• Actual Revenue: $8.90 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sunshine Biopharma Announcement Details

• Quarter: Q1 2025
• Date: 5/15/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Sunshine Biopharma (NASDAQ:SBFM) is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies. These molecules are engineered to enhance tumor selectivity and minimize cardiotoxicity commonly associated with traditional anthracyclines.

The company is headquartered in Montreal, Canada, and operates research facilities in North America. Sunshine Biopharma collaborates with academic institutions and contract research organizations to conduct preclinical studies and regulatory activities. Leadership is headed by Dr. Bhupinder Kaur Singh, who serves as President and Chief Executive Officer, guiding corporate strategy, research priorities and investor relations.